Tumor-associated antigens derived from autologous and allogeneic glioblastoma cells (GBM-TAAs)

Tumor-associated antigens (TAAs) derived from autologous and allogeneic glioblastoma cells represent a complex therapeutic target used in the development of personalized cancer vaccines. This target is not a single molecule but a heterogeneous mixture of proteins and peptides extracted from both the patient's own tumor (autologous) and donor glioblastoma cell lines (allogeneic) (Bota et al., 2022, Journal of Clinical Oncology). The biological rationale for using this broad antigenic spectrum is to address the high degree of intratumoral heterogeneity and clonal evolution characteristic of glioblastoma multiforme (GBM), which often leads to resistance in single-target therapies (Sottoriva et al., 2013, PNAS). When administered as a vaccine, such as ERC1671 (Gliovac), these antigens are intended to prime the host immune system to recognize and attack malignant cells throughout the brain (Schijns et al., 2015, OncoImmunology). This process involves the activation of both helper (CD4+) and cytotoxic (CD8+) T cells, as well as the potential induction of a B-cell mediated antibody response (NCI Drug Dictionary). By combining autologous antigens, which capture patient-specific mutations, with allogeneic antigens that provide common GBM markers, the therapy seeks to minimize the risk of antigen escape (Bota et al., 2022, Journal of Clinical Oncology). Clinical challenges include the potential for autoimmune cross-reactivity with healthy neural tissue and the highly immunosuppressive environment of the central nervous system.

Other names

Glioblastoma tumor-associated antigensAutologous and allogeneic tumor cell lysateGBM antigensTumor-specific antigens

Active immunotherapy involving the presentation of a diverse pool of autologous and allogeneic tumor antigens to stimulate a comprehensive immune response against glioblastoma cells (Bota et al., 2022, Journal of Clinical Oncology).